ChemoMetec A/S (CPH:CHEMM)

Market Cap	11.35B
Revenue (ttm)	495.57M
Net Income (ttm)	186.41M
Shares Out	17.40M
EPS (ttm)	10.71
PE Ratio	60.88
Forward PE	50.15
Dividend	7.00 (1.07%)
Ex-Dividend Date	Oct 10, 2025

Volume	5,691
Average Volume	29,253
Open	660.50
Previous Close	652.00
Day's Range	653.00 - 662.50
52-Week Range	339.00 - 703.00
Beta	1.59
RSI	58.19
Earnings Date	Feb 4, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 170
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: CHEMM

Financial Performance

In 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.